Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 13/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605301 | 0.85 | CCR3 (0.48) | CCR3CYP2D6BRD4 | |
| SCHEMBL4606996 | 0.82 | CCR3 (0.68) | CCR3CYP2D6 | |
| SCHEMBL4604702 | 0.81 | CCR3 (0.64) | CCR3CYP2D6 | |
| SCHEMBL6336137 | 0.78 | CCR3 (0.75) | CCR3CYP2D6 | |
| SCHEMBL4738080 | 0.76 | CCR3 (0.56) | CCR3CYP2D6 | |
| SCHEMBL4881257 | 0.76 | HDAC3 (0.49) | CCR3CYP2D6KMT2AMEN1PRMT3 | |
| SCHEMBL4872393 | 0.75 | CCR3 (0.55) | CCR3CYP2D6 | |
| SCHEMBL20630845 | 0.74 | PTK2 (0.47) | CCR3ALDH1A1 | |
| SCHEMBL4880232 | 0.74 | CCR3 (0.65) | CCR3CYP2D6 | |
| SCHEMBL4604891 | 0.74 | CCR3 (0.69) | CCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| CN-101296911-A | Arylurea derivatives as modulators of chemokine receptor activity | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | CCR3 1/4885CYP2D6 2500/4885KMT2A 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.